Cargando…
Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556670/ https://www.ncbi.nlm.nih.gov/pubmed/33054094 http://dx.doi.org/10.3324/haematol.2019.243170 |
| _version_ | 1783594269953490944 |
|---|---|
| author | Stefoni, Vittorio Marangon, Miriam Re, Alessandro Lleshi, Arben Bonfichi, Maurizio Pinto, Antonello Bianchetti, Nicola Pellegrini, Cinzia Argnani, Lisa Zinzani, Pier Luigi |
| author_facet | Stefoni, Vittorio Marangon, Miriam Re, Alessandro Lleshi, Arben Bonfichi, Maurizio Pinto, Antonello Bianchetti, Nicola Pellegrini, Cinzia Argnani, Lisa Zinzani, Pier Luigi |
| author_sort | Stefoni, Vittorio |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7556670 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Fondazione Ferrata Storti |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-75566702020-10-15 Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS Stefoni, Vittorio Marangon, Miriam Re, Alessandro Lleshi, Arben Bonfichi, Maurizio Pinto, Antonello Bianchetti, Nicola Pellegrini, Cinzia Argnani, Lisa Zinzani, Pier Luigi Haematologica Letters to the Editor Fondazione Ferrata Storti 2020-02-13 /pmc/articles/PMC7556670/ /pubmed/33054094 http://dx.doi.org/10.3324/haematol.2019.243170 Text en Copyright© 2020 Ferrata Storti Foundation http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
| spellingShingle | Letters to the Editor Stefoni, Vittorio Marangon, Miriam Re, Alessandro Lleshi, Arben Bonfichi, Maurizio Pinto, Antonello Bianchetti, Nicola Pellegrini, Cinzia Argnani, Lisa Zinzani, Pier Luigi Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS |
| title | Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS |
| title_full | Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS |
| title_fullStr | Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS |
| title_full_unstemmed | Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS |
| title_short | Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS |
| title_sort | brentuximab vedotin in the treatment of elderly hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase ii study of fil onlus |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556670/ https://www.ncbi.nlm.nih.gov/pubmed/33054094 http://dx.doi.org/10.3324/haematol.2019.243170 |
| work_keys_str_mv | AT stefonivittorio brentuximabvedotininthetreatmentofelderlyhodgkinlymphomapatientsatfirstrelapseorwithprimaryrefractorydiseaseaphaseiistudyoffilonlus AT marangonmiriam brentuximabvedotininthetreatmentofelderlyhodgkinlymphomapatientsatfirstrelapseorwithprimaryrefractorydiseaseaphaseiistudyoffilonlus AT realessandro brentuximabvedotininthetreatmentofelderlyhodgkinlymphomapatientsatfirstrelapseorwithprimaryrefractorydiseaseaphaseiistudyoffilonlus AT lleshiarben brentuximabvedotininthetreatmentofelderlyhodgkinlymphomapatientsatfirstrelapseorwithprimaryrefractorydiseaseaphaseiistudyoffilonlus AT bonfichimaurizio brentuximabvedotininthetreatmentofelderlyhodgkinlymphomapatientsatfirstrelapseorwithprimaryrefractorydiseaseaphaseiistudyoffilonlus AT pintoantonello brentuximabvedotininthetreatmentofelderlyhodgkinlymphomapatientsatfirstrelapseorwithprimaryrefractorydiseaseaphaseiistudyoffilonlus AT bianchettinicola brentuximabvedotininthetreatmentofelderlyhodgkinlymphomapatientsatfirstrelapseorwithprimaryrefractorydiseaseaphaseiistudyoffilonlus AT pellegrinicinzia brentuximabvedotininthetreatmentofelderlyhodgkinlymphomapatientsatfirstrelapseorwithprimaryrefractorydiseaseaphaseiistudyoffilonlus AT argnanilisa brentuximabvedotininthetreatmentofelderlyhodgkinlymphomapatientsatfirstrelapseorwithprimaryrefractorydiseaseaphaseiistudyoffilonlus AT zinzanipierluigi brentuximabvedotininthetreatmentofelderlyhodgkinlymphomapatientsatfirstrelapseorwithprimaryrefractorydiseaseaphaseiistudyoffilonlus |